Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCM HUTCHMED	$17.61 -1.0%	$15.50	$11.51 ▼ $21.50	$3.10B	0.52	55,714 shs	8,848 shs
IMVT Immunovant	$16.95 -7.5%	$16.23	$12.72 ▼ $34.47	$3.13B	0.63	1.14 million shs	4.51 million shs
KALV KalVista Pharmaceuticals	$14.58 -6.5%	$13.20	$7.30 ▼ $16.32	$779.28M	-0.04	1.81 million shs	1.01 million shs
KYMR Kymera Therapeutics	$45.79 -0.1%	$42.50	$19.44 ▼ $53.27	$2.99B	2.18	772,263 shs	362,476 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCM HUTCHMED	+1.20%	+1.48%	+12.25%	+21.70%	-5.12%
IMVT Immunovant	-0.38%	+0.22%	+14.50%	+24.46%	-34.43%
KALV KalVista Pharmaceuticals	+0.26%	-2.56%	+33.33%	+20.09%	+7.81%
KYMR Kymera Therapeutics	-1.25%	-1.08%	-2.74%	+37.85%	+6.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HCM HUTCHMED	2.7778 of 5 stars	3.2	3.0	0.0	2.9	0.0	1.9
IMVT Immunovant	1.6052 of 5 stars	3.4	0.0	0.0	3.3	1.7	0.0
KALV KalVista Pharmaceuticals	4.1141 of 5 stars	3.6	1.0	4.4	3.4	1.7	0.6
KYMR Kymera Therapeutics	3.0325 of 5 stars	4.5	1.0	0.0	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCM HUTCHMED	2.33	Hold	$23.50	33.45% Upside
IMVT Immunovant	2.82	Moderate Buy	$36.30	114.16% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	80.29% Upside
KYMR Kymera Therapeutics	3.05	Buy	$59.11	29.09% Upside

Current Analyst Ratings Breakdown

Latest KALV, HCM, IMVT, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $28.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00

(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCM HUTCHMED	$630.20M	4.87	$0.28 per share	61.90	$4.43 per share	3.98
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
KYMR Kymera Therapeutics	$47.07M	63.35	N/A	N/A	$12.90 per share	3.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCM HUTCHMED	$37.73M	N/A	0.00	12.06	N/A	N/A	N/A	N/A	8/7/2025 (Estimated)
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)

Latest KALV, HCM, IMVT, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.84	N/A	N/A	N/A	$17.37 million	N/A
8/5/2025	Q1 2026	IMVT Immunovant	-$0.69	N/A	N/A	N/A	N/A	N/A
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCM HUTCHMED	0.08	2.83	2.70
IMVT Immunovant	N/A	11.16	11.16
KALV KalVista Pharmaceuticals	N/A	5.35	5.35
KYMR Kymera Therapeutics	N/A	8.49	8.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCM HUTCHMED	8.82%
IMVT Immunovant	47.08%
KALV KalVista Pharmaceuticals	N/A
KYMR Kymera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
HCM HUTCHMED	3.60%
IMVT Immunovant	1.80%
KALV KalVista Pharmaceuticals	10.50%
KYMR Kymera Therapeutics	16.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
KALV KalVista Pharmaceuticals	100	49.95 million	44.71 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable

KALV, HCM, IMVT, and KYMR Headlines

Recent News About These Companies

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Buy" from Brokerages

July 22 at 2:29 AM | americanbankingnews.com

Jennison Associates LLC Sells 164,647 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

July 21, 2025 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Upgraded at The Goldman Sachs Group

July 18, 2025 | marketbeat.com

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

July 18, 2025 | zacks.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Analysts

July 17, 2025 | marketbeat.com

Kymera Therapeutics Inc (KYMR) - Investing.com

July 11, 2025 | investing.com

Q3 EPS Estimate for Kymera Therapeutics Raised by Analyst

July 9, 2025 | marketbeat.com

Kymera Therapeutics (KYMR) director group buys $13.9 million in stock

July 3, 2025 | investing.com

Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated at Morgan Stanley

July 3, 2025 | marketbeat.com

Tuesday’s Insider Activity: Major Buys and Sells Shake Up Markets

July 3, 2025 | investing.com

Insider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Buys 317,167 Shares of Stock

July 2, 2025 | insidertrades.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bvf Partners L. P/Il Purchases 317,167 Shares

July 1, 2025 | marketbeat.com

Bros. Advisors Lp Baker Purchases 655,500 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

July 1, 2025 | insidertrades.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bros. Advisors Lp Baker Buys 655,500 Shares

June 30, 2025 | marketbeat.com

HC Wainwright Has Strong Forecast for KYMR FY2026 Earnings

June 30, 2025 | marketbeat.com

KYMR Q3 EPS Estimate Reduced by Brookline Capital Management

June 30, 2025 | marketbeat.com

Oppenheimer Cuts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $53.00

June 27, 2025 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading Volume - Time to Buy?

June 27, 2025 | marketbeat.com

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

June 26, 2025 | globenewswire.com

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 4.1% Following Analyst Downgrade

June 26, 2025 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Price Target Lowered to $53.00 at Wells Fargo & Company

June 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV, HCM, IMVT, and KYMR Company Descriptions

HUTCHMED NASDAQ:HCM

$17.61 -0.17 (-0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$17.74 +0.13 (+0.71%)

As of 04:46 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Immunovant NASDAQ:IMVT

$16.95 -1.37 (-7.48%)

Closing price 04:00 PM Eastern

Extended Trading

$17.14 +0.20 (+1.15%)

As of 06:46 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

KalVista Pharmaceuticals NASDAQ:KALV

$14.58 -1.02 (-6.54%)

Closing price 04:00 PM Eastern

Extended Trading

$14.84 +0.26 (+1.78%)

As of 07:48 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Kymera Therapeutics NASDAQ:KYMR

$45.79 -0.06 (-0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$45.79 0.00 (0.00%)

As of 04:11 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time